MX370923B - Formulacion de relacion fija de insulina glargina/lixisenatida. - Google Patents

Formulacion de relacion fija de insulina glargina/lixisenatida.

Info

Publication number
MX370923B
MX370923B MX2015017540A MX2015017540A MX370923B MX 370923 B MX370923 B MX 370923B MX 2015017540 A MX2015017540 A MX 2015017540A MX 2015017540 A MX2015017540 A MX 2015017540A MX 370923 B MX370923 B MX 370923B
Authority
MX
Mexico
Prior art keywords
fixed ratio
insulin glargine
ratio formulation
lixisenatide fixed
lixisenatide
Prior art date
Application number
MX2015017540A
Other languages
English (en)
Other versions
MX2015017540A (es
Inventor
Silvestre Louise
Souhami Elisabeth
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50933180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX370923(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MX2015017540A publication Critical patent/MX2015017540A/es
Publication of MX370923B publication Critical patent/MX370923B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende (a) lixisenatida o/y una sal farmacéuticamente aceptable de la misma, en donde el compuesto (b) está presente a una concentración de 100 U/ml y el compuesto (a) está presente a una concentración de 50 µg/ml para usarse en el tratamiento de diabetes mellitus tipo 2, en donde la composición farmacéuticamente está formulada para ser administrable como un complemento al tratamiento con mtformina o/y una sal farmacéuticamente aceptable de la misma.
MX2015017540A 2013-06-17 2014-06-13 Formulacion de relacion fija de insulina glargina/lixisenatida. MX370923B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13172341 2013-06-17
EP13192556 2013-11-12
PCT/EP2014/062418 WO2014202483A1 (en) 2013-06-17 2014-06-13 Insulin glargine/lixisenatide fixed ratio formulation

Publications (2)

Publication Number Publication Date
MX2015017540A MX2015017540A (es) 2016-08-08
MX370923B true MX370923B (es) 2020-01-09

Family

ID=50933180

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015017540A MX370923B (es) 2013-06-17 2014-06-13 Formulacion de relacion fija de insulina glargina/lixisenatida.

Country Status (25)

Country Link
US (4) US20140371141A1 (es)
EP (1) EP3010530B1 (es)
JP (1) JP6438944B2 (es)
KR (1) KR102231074B1 (es)
CN (1) CN105473155B (es)
AU (1) AU2014283423B2 (es)
CA (1) CA2915413A1 (es)
CL (1) CL2015003634A1 (es)
CY (1) CY1121881T1 (es)
DK (1) DK3010530T3 (es)
ES (1) ES2723887T3 (es)
HK (1) HK1217429A1 (es)
HR (1) HRP20190557T1 (es)
HU (1) HUE042796T2 (es)
IL (1) IL242831B (es)
LT (1) LT3010530T (es)
MX (1) MX370923B (es)
PH (1) PH12015502755A1 (es)
PL (1) PL3010530T3 (es)
PT (1) PT3010530T (es)
RU (1) RU2684398C2 (es)
SG (2) SG11201509781YA (es)
SI (1) SI3010530T1 (es)
WO (1) WO2014202483A1 (es)
ZA (1) ZA201508719B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
UY33025A (es) 2009-11-13 2011-06-30 Sanofi Aventis Deustschland Gmbh Composicion farmaceutica que comprende un agonista de glp-1 metionina
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN107206058A (zh) * 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) * 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
PT3229828T (pt) * 2015-11-10 2023-06-29 Sanofi Aventis Deutschland Formulação de razão fixa de insulina glargina/lixisenatido
WO2018055539A1 (en) * 2016-09-22 2018-03-29 Wockhardt Limited Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue
US20210093698A1 (en) 2019-09-13 2021-04-01 Sanofi Treatment of type 2 diabetes mellitus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3228320B1 (de) * 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
DE102008053048A1 (de) * 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
ME01546B (me) * 2009-11-13 2014-04-20 Sanofi Aventis Deutschland Liksisenatid kao dodatna terapija insulin glarginu i metforminu za liječenje dijabetesa tipa 2
JP5980466B2 (ja) * 2009-11-13 2016-08-31 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン及びメトホルミンへの付加療法を含む2型糖尿病の治療方法
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2389945A1 (en) * 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine

Also Published As

Publication number Publication date
HRP20190557T1 (hr) 2019-05-03
EP3010530A1 (en) 2016-04-27
HK1217429A1 (zh) 2017-01-13
AU2014283423B2 (en) 2019-03-14
CN105473155A (zh) 2016-04-06
CY1121881T1 (el) 2020-10-14
LT3010530T (lt) 2019-04-10
MX2015017540A (es) 2016-08-08
KR20160020491A (ko) 2016-02-23
SG11201509781YA (en) 2015-12-30
WO2014202483A1 (en) 2014-12-24
US20220031811A1 (en) 2022-02-03
US20140371141A1 (en) 2014-12-18
RU2016101064A (ru) 2017-07-20
US20200038488A1 (en) 2020-02-06
AU2014283423A1 (en) 2016-01-07
PL3010530T4 (pl) 2019-07-31
JP6438944B2 (ja) 2018-12-19
PH12015502755A1 (en) 2016-03-21
HUE042796T2 (hu) 2019-07-29
JP2016521720A (ja) 2016-07-25
RU2016101064A3 (es) 2018-04-25
EP3010530B1 (en) 2018-12-26
NZ715144A (en) 2021-06-25
ZA201508719B (en) 2017-07-26
US11026999B2 (en) 2021-06-08
IL242831B (en) 2019-12-31
RU2684398C2 (ru) 2019-04-09
US20180133290A1 (en) 2018-05-17
CL2015003634A1 (es) 2016-08-12
CA2915413A1 (en) 2014-12-24
SI3010530T1 (sl) 2019-05-31
ES2723887T3 (es) 2019-09-03
SG10201710347PA (en) 2018-01-30
CN105473155B (zh) 2020-02-07
PT3010530T (pt) 2019-04-18
KR102231074B1 (ko) 2021-03-22
DK3010530T3 (en) 2019-04-15
PL3010530T3 (pl) 2019-07-31

Similar Documents

Publication Publication Date Title
PH12015502755A1 (en) Insulin glargine / lixisenatide fixed ratio formulation
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
HK1226302A1 (zh) 穩定的促胰島素分泌肽水針藥物組合物
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
HK1222563A1 (zh) 藥物組合物、製備及其用途
PH12015501096A1 (en) Composition for immediate and extended release
MX2015016676A (es) Soluciones orales estables para api combinados.
WO2011144674A3 (en) PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
HK1211021A1 (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions 2--6--9--9h-
EP3048103A4 (en) Immune adjustment compound, use thereof and pharmaceutical composition comprising same
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE
HK1221425A1 (zh) 芋螺毒素 肽,其醫藥組合物和用途
WO2015173427A3 (fr) Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
EP3020417A4 (en) Pharmaceutical composition for respiratory administration
EP2941418A4 (en) N1-CYCLIC AMIN-N5 SUBSTITUTED BIGUANIDE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
WO2014122460A3 (en) Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
IL284405A (en) Pharmaceutical composition, preparation and uses thereof
UA90602U (uk) Фармацевтична композиція комбінованої дії

Legal Events

Date Code Title Description
FG Grant or registration